Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791452 | 1.00 | MAPT (0.54) | MAPTRAB9ANPC1PRKCIDYRK1A | |
| SCHEMBL577552 | 0.88 | CLK1 (0.46) | MAPTRAB9ANPC1PRKCIDYRK1A | |
| SCHEMBL29397421 | 0.88 | CLK1 (0.46) | MAPTRAB9ANPC1PRKCIDYRK1A | |
| Oxirane SCHEMBL27706875 | 0.84 | ALK (0.44) | MAPTRAB9ANPC1PRKCIDYRK1A | |
| SCHEMBL27310562 | 0.84 | MAPT (0.64) | MAPTRAB9ANPC1PRKCIDYRK1A | |
| SCHEMBL30410306 | 0.83 | MAPT (0.43) | MAPTRAB9ANPC1PRKCIKDM4E | |
| SCHEMBL8342110 | 0.83 | MAPT (0.43) | MAPTRAB9ANPC1PRKCIKDM4E | |
| SCHEMBL29692961 | 0.76 | FABP6 (0.39) | MAPTRAB9ANPC1PRKCIKDM4E | |
| SCHEMBL17927769 | 0.75 | FABP6 (0.49) | MAPTRAB9ANPC1FABP6RIPK1 | |
| SCHEMBL2924947 | 0.75 | CTNNB1 (0.53) | MAPTRAB9ANPC1KDM4EFABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | claimed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | claimed |
| CN-101124220-A | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-02-13 | — | — | CN | claimed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | claimed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | claimed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | claimed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025016457-A1 | NEW SUBSTITUTED HETEROCYCLIC COMPOUND AS GSPTS/MYC SIGNAL FLUX REGULATOR | 杭州德睿智药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4562267-A | Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1985-12-31 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4423233-A | ALPHA-HYDROXY CARBOXIMIDATE INTERMEDIATES | PFIZER INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4381308-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-04-26 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4332952-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | MAPT 2773/4885RAB9A 1415/4885NPC1 2036/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | MAPT 4795/4885RAB9A 3175/4885NPC1 285/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | MAPT 3641/4885RAB9A 1122/4885NPC1 4048/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | MAPT 4193/4885RAB9A 467/4885NPC1 558/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | MAPT 4210/4885RAB9A 1841/4885NPC1 2427/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | MAPT 3874/4885RAB9A 2161/4885NPC1 2146/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | MAPT 4210/4885RAB9A 1841/4885NPC1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.